Aclaris Therapeutics, Inc. (ACRS) Net margin 2017–2025
Aclaris Therapeutics, Inc. (ACRS) net profit margin by fiscal year — reported net income divided by reported revenue.
-829.6%FY2025 · since FY2017: -4071.5% → -829.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -829.6% | -124.1 pp |
| FY2024 | -705.5% | -422.3 pp |
| FY2023 | -283.1% | +9.0 pp |
| FY2022 | -292.1% | +1051.8 pp |
| FY2021 | -1344.0% | -556.9 pp |
| FY2020 | -787.0% | +3030.2 pp |
| FY2019 | -3817.2% | -1659.2 pp |
| FY2018 | -2158.0% | +1913.5 pp |
| FY2017 | -4071.5% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More ACRS financial trends
ACRS RevenueACRS Net incomeACRS Gross profitACRS Gross marginACRS Operating incomeACRS Operating marginACRS Operating cash flowACRS Free cash flowACRS Capital expendituresACRS Return on equityACRS Stock buybacksACRS Dividends paidACRS Total assetsACRS Total liabilitiesACRS Shareholders’ equityACRS overview →